ÂÜÀòÂÒÂ×

Karen Tubridy has served as Chief Development Officer of Verseau since September 2021. Karen brings over 25 years of experience in clinical operations management as well as in research and development of novel and first-in-class therapeutics, including overall drug development strategy and operations. Karen previously served as Senior Vice President, Global Programs and Chief Development Officer at Akebia Therapeutics, where she was responsible for driving program strategy with operational responsibilities for its lead clinical asset through NDA and J-NDA. Prior to joining Akebia, Karen was Chief Development Officer at Eleven Biotherapeutics, where she led clinical, regulatory, quality, program management and development strategy. She previously served as Senior Vice President, Clinical Development and Medical Affairs at Inspiration Biopharmaceuticals. Before this, she held senior positions in clinical and regulatory operations at Taligen Therapeutics and stayed on following the company’s acquisition by Alexion Pharmaceuticals. Karen also served as Vice President, Clinical Operations at Syntonix Pharmaceuticals and Biogen Idec Hemophilia. She held a senior position at AVANT Immunotherapeutics and held positions of increasing responsibility in clinical research and medical affairs at Genetics Institute/Wyeth Pharmaceuticals, where she directed the hematology and oncology programs. Karen holds a B.S. in pharmacy and a Pharm.D. from the Massachusetts College of Pharmacy and Allied Health Sciences.